STOCK TITAN

uniQure (NASDAQ: QURE) director trades options and shares on Form 4 filing

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

uniQure director Robert Gut reported option exercises and share sales in the company’s ordinary shares. On January 12, 2026, he exercised a stock option for 17,810 ordinary shares at $14.08 per share, converting derivative securities into directly held stock.

On the same date, he sold ordinary shares in several transactions: 17,310 shares at a weighted average price of $24.39 (with individual sale prices between $24.02 and $25.00), 500 shares at a weighted average price of $25.03 (with prices between $25.02 and $25.04), and 7,803 shares at $25.09. After these trades, he directly owned 32,342 ordinary shares. All transactions were carried out under a Rule 10b5-1 trading plan adopted on July 8, 2025.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gut Robert

(Last) (First) (Middle)
C/O UNIQURE N.V.
PAASHEUVELWEG 25A

(Street)
AMSTERDAM P7 11058BP

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 01/12/2026 M(1) 17,810 A $14.08 57,955 D
Ordinary Shares 01/12/2026 S(1) 17,310 D $24.39(2) 40,645 D
Ordinary Shares 01/12/2026 S(1) 500 D $25.03(3) 40,145 D
Ordinary Shares 01/12/2026 S(1) 7,803 D $25.09 32,342 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.08 01/12/2026 M(1) 17,810 (4) 06/15/2032 Ordinary Shares 17,810 $0 0 D
Explanation of Responses:
1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.02 to $25.00. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.02 to $25.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The Stock Option vested in full on June 15, 2023.
/s/ Christian Klemt, Attorney-in-Fact 01/14/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading uniQure (QURE) shares in this Form 4?

The Form 4 reports transactions by Robert Gut, who is a director of uniQure N.V. and files as a single reporting person.

What options did Robert Gut exercise in uniQure (QURE)?

He exercised a stock option (right to buy) for 17,810 ordinary shares at an exercise price of $14.08 per share on January 12, 2026. The option had vested in full on June 15, 2023 and carried an expiration date of June 15, 2032.

How many uniQure (QURE) shares did the director sell and at what prices?

On January 12, 2026, he reported sales of 17,310 ordinary shares at a weighted average price of $24.39 (with sale prices ranging from $24.02 to $25.00), 500 shares at a weighted average price of $25.03 (with prices from $25.02 to $25.04), and 7,803 shares at $25.09.

How many uniQure (QURE) shares does Robert Gut own after these transactions?

Following the reported transactions on January 12, 2026, Robert Gut directly owned 32,342 ordinary shares of uniQure N.V..

Were Robert Gut’s uniQure (QURE) trades made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected under a sales plan adopted on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

Are the reported sale prices for uniQure (QURE) shares exact or weighted averages?

The prices of $24.39 and $25.03 per share are reported as weighted average prices, with the filing noting that the shares were sold in multiple transactions within specified price ranges and that detailed breakdowns are available on request.
Uniqure

NASDAQ:QURE

View QURE Stock Overview

QURE Rankings

QURE Latest News

QURE Latest SEC Filings

QURE Stock Data

1.10B
58.16M
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
AMSTERDAM